Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vanda Pharmaceuticals

4.77
-0.1500-3.05%
Post-market: 4.770.00000.00%16:41 EDT
Volume:606.44K
Turnover:2.92M
Market Cap:278.17M
PE:-14.45
High:4.96
Open:4.95
Low:4.75
Close:4.92
Loading ...

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

THOMSON REUTERS
·
27 Jan

Vanda Pharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Jan

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

Benzinga
·
17 Jan

Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner

MT Newswires Live
·
09 Jan

Vanda Pharmaceuticals: Issued Letter to FDA Regarding Sept. 18, 2024 Crl in Reference to Co's Nda for Tradipitant for Treatment of Gastroparesis

THOMSON REUTERS
·
09 Jan

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis Nda Review

THOMSON REUTERS
·
09 Jan

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

PR Newswire
·
09 Jan

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Zacks
·
07 Jan

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Zacks
·
07 Jan

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Zacks
·
06 Jan

The #1 growth stocks set to explode in 2025

LiveWire
·
06 Jan

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks
·
24 Dec 2024

Vanda Pharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Dec 2024

Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation

MT Newswires Live
·
20 Dec 2024

Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment

Dow Jones
·
20 Dec 2024

Vanda Pharmaceuticals: Orphan Drug Designation Granted for VGT-1849A

TIPRANKS
·
20 Dec 2024